MONMOUTH JUNCTION, N.J.,
Nov. 14, 2011 /PRNewswire/ -- Insmed
Incorporated (Nasdaq CM: INSM), a biopharmaceutical company,
announced today that Timothy
Whitten, President and CEO of Insmed, will be presenting a
corporate overview at the Lazard Capital Markets 8th Annual
Healthcare Conference on Wednesday, November
16, 2011, at 8:30 AM ET, in
New York.
A live audio webcast will be available on Insmed's website,
http://www.insmed.com. The webcast will also be archived for
90 days.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on
the development of innovative inhaled pharmaceuticals for the
site-specific treatment of serious lung diseases, and has a
proprietary protein platform aimed at niche markets with high unmet
medical need. Insmed's primary focus is on the development of
inhaled antibiotic therapy delivered via proprietary advanced
pulmonary liposome technology in areas of high unmet need in lung
diseases. For more information, please visit
http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Investors are cautioned that such statements in
this release, including statements relating to our financial
position, results of operations, the status and the results of
preclinical studies and clinical trials and preclinical and
clinical data described herein, the timing of responses to
information and data requests from FDA, the development of our
products, and the business strategies, evaluations, plans, and
objectives of management, constitute forward-looking statements
which involve risks and uncertainties that could cause actual
results to differ materially from those anticipated by the
forward-looking statements. Our results may be affected by
such factors as the receipt and timing of FDA and other regulatory
reviews and approvals, if at all, competitive developments
affecting our product development, delays in product development or
clinical trials, and patent disputes involving currently developing
products. The risks and uncertainties include, without
limitation, we may experience unexpected regulatory actions, delays
or requests, our future clinical trials may not be successful, we
may be unsuccessful in developing our product candidates or
receiving necessary regulatory approvals, we may experience delays
in our product development or clinical trials, our product
candidates may not prove to be commercially successful, our
expenses may be higher than anticipated and other risks and
challenges detailed in our filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the year ended December 31, 2010 and
our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2011. Investors are
cautioned not to place undue reliance on any forward-looking
statements which speak only as of the date of this release.
We undertake no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made
to reflect events or circumstances that occur after the date of
this release or to reflect the occurrence of unanticipated
events.
Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.com
Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com
SOURCE Insmed Incorporated